Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/34627
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMedina, Susana
dc.contributor.authorGómez-Zubiaur, Alba
dc.contributor.authorValdeolivas-Casillas, Nuria
dc.contributor.authorPolo-Rodríguez, Isabel
dc.contributor.authorRuíz, Lucia
dc.contributor.authorIzquierdo, Carmen
dc.contributor.authorGuirado, Cristina
dc.contributor.authorCabrera, Alicia
dc.contributor.authorTrasobares, Lidia
dc.date.accessioned2019-06-28T17:39:06Z-
dc.date.available2019-06-28T17:39:06Z-
dc.date.issued2018-12
dc.identifier.citationEur J Rheumatol.2018 Dec;(5)4:224-229
dc.identifier.issn2147-9720
dc.identifier.urihttps://hdl.handle.net/20.500.12530/34627-
dc.description.abstractRaynaud's phenomenon consists of vasospastic disease of the digital arteries after exposure to cold or stress. It causes an important reduction in the patient's quality of life when severe. The available treatments do not always offer favorable results.
dc.language.isoeng
dc.rightsopenAccess-
dc.titleBotulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study.
dc.typeArtículo
dc.identifier.pubmedID30501848
dc.format.volume5
dc.format.page224-229
dc.identifier.journalEuropean journal of rheumatology
dc.identifier.doi10.5152/eurjrheum.2018.18013
dc.format.number4
dc.identifier.pmcPMC6267752
dc.pubmedtypeJournal Article
Appears in Collections:Hospitales > H. U. Sureste > Artículos
Fundaciones e Institutos de Investigación > FIB H. U. Príncipe de Asturias > Artículos

Files in This Item:
File Description SizeFormat 
PMC6267752.pdf1.36 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.